Management of Gross Hematuria After Antiplatelet Initiation Post-Embolic Stroke

Immediate Post-Bleeding Management

• The Canadian Stroke Best Practice guidelines emphasize that antiplatelet therapy should be continued indefinitely after acute stroke unless there is active, uncontrolled bleeding 1, 2
• Resume aspirin (81-325 mg daily) as soon as the hematuria has cleared with CBI, as the risk of recurrent embolic stroke significantly outweighs the bleeding risk in this clinical scenario 1, 2

Risk-Benefit Assessment

• In embolic stroke patients, the absolute risk of recurrent stroke without antiplatelet therapy is substantially higher than the risk of recurrent hematuria 1, 4
• For elderly patients specifically, while bleeding risk is elevated, the mortality and morbidity from recurrent embolic stroke is catastrophic 3

Urological Follow-Up Protocol

• Schedule urgent urology consultation within 1-2 weeks to evaluate for underlying bladder pathology 3
• Gross hematuria in an elderly patient on antiplatelet therapy may unmask underlying malignancy or other structural lesions that would have eventually bled regardless of antiplatelet use 3

Antiplatelet Regimen Optimization

• If this was an embolic stroke from a cardioembolic source (e.g., atrial fibrillation), anticoagulation—not antiplatelet therapy—is the appropriate long-term treatment 4
• Consider aspirin monotherapy rather than dual therapy to reduce bleeding risk while maintaining stroke prevention 1, 3

Bleeding Risk Mitigation Strategies

• Add a proton pump inhibitor (PPI) for gastrointestinal protection, particularly important in elderly patients on antiplatelet therapy 1, 2, 6
• Ensure strict blood pressure control (target <130/80 mmHg) to reduce risk of both recurrent stroke and bleeding complications 1

Common Pitfalls to Avoid

• Do not withhold antiplatelet therapy indefinitely after a single episode of hematuria that has resolved—this dramatically increases stroke recurrence risk and mortality 1, 3
• Do not assume the hematuria was solely due to antiplatelet therapy without urological investigation—elderly patients require cancer screening regardless 3

Long-Term Management Plan

• Week 1: Verify hematuria resolution, check hemoglobin, ensure antiplatelet compliance 3
• Month 3: If on dual antiplatelet therapy, transition to monotherapy at this point 1, 2, 5